Verona Pharma plc Sponsored ADR Aktie News

Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projects Verona Pharma's sales to reach $1 billion by 2028, fueled by its safety profile and the unmet needs of those 398 million COPD sufferers worldwide. Global expansion, robust patent protection, and...

If you want to achieve significant gains in the stock market, you'll probably want to plan to hold on and remain invested for many years, or even decades. But in some cases, big payoffs can come much faster than that.

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population

VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favor...

Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Tara Rheault - Chief Development Officer Kathleen Rickard - Chief Medical Officer Conference Call Participants Andrew Tsai - Jeffer...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024)

Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose c...